Solrikitug
COPD
Key Facts
About Uniquity Bio
Uniquity Bio is a private, clinical-stage biotech founded in 2022 and headquartered in New York, USA. The company is building a pipeline in immunology and inflammation, anchored by its lead in-licensed asset, solrikitug (anti-TSLP mAb), which is currently in Phase 2 trials for COPD, asthma, and eosinophilic esophagitis (EoE). Backed by Blackstone Life Sciences, Uniquity combines experienced leadership with committed capital to strategically identify and advance under-explored therapeutic opportunities for patients with limited treatment options.
View full company profileAbout Uniquity Bio
Uniquity Bio is a private, clinical-stage biotech founded in 2022 and headquartered in New York, USA. The company is building a pipeline in immunology and inflammation, anchored by its lead in-licensed asset, solrikitug (anti-TSLP mAb), which is currently in Phase 2 trials for COPD, asthma, and eosinophilic esophagitis (EoE). Backed by Blackstone Life Sciences, Uniquity combines experienced leadership with committed capital to strategically identify and advance under-explored therapeutic opportunities for patients with limited treatment options.
View full company profileAbout Uniquity Bio
Uniquity Bio is a private, clinical-stage biotech founded in 2022 and headquartered in New York, USA. The company is building a pipeline in immunology and inflammation, anchored by its lead in-licensed asset, solrikitug (anti-TSLP mAb), which is currently in Phase 2 trials for COPD, asthma, and eosinophilic esophagitis (EoE). Backed by Blackstone Life Sciences, Uniquity combines experienced leadership with committed capital to strategically identify and advance under-explored therapeutic opportunities for patients with limited treatment options.
View full company profileTherapeutic Areas
Other COPD Drugs
| Drug | Company | Phase |
|---|---|---|
| Yupelri® (revefenacin) | Cleo Life Sciences | Approved |
| Spiro Neuromodulation System | Spiro Medical | Phase 2 |
| VL-PX10 & VL-P22 | Vitti Labs | Phase 2 |
| CAL-4 | Calyxha Biotechnologies | Discovery |
| OligoG (Inhaled) | Algipharma | Phase 2 |
| Digital Biomarker for COPD | electronRx | Early Development |
| Tozorakimab | AstraZeneca | Phase III |
| Eclira Genuair (Acidinium Bromide) | KYORIN Pharmaceutical | Marketed |
| ANORO ELLIPTA | Innoviva | Commercial |
| GB-0895 | Generate Biomedicines | Phase 1 |